Literature DB >> 26732876

Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study.

Massimiliano Bissolati1, Matteo Desio2, Fausto Rosa3, Stefano Rausei4, Daniele Marrelli5, Gian Luca Baiocchi6, Giovanni De Manzoni7, Damiano Chiari2, Giovanni Guarneri2, Fabio Pacelli3, Lorenzo De Franco5, Sarah Molfino6, Chiara Cipollari7, Elena Orsenigo2.   

Abstract

BACKGROUND: Resection margin (RM) involvement is associated with negative prognosis after gastrectomy. Intraoperative frozen section (IFS) analysis allows radical resection to be achieved in a single operation but is time-consuming and resource-consuming. The aim of this study was to assess risk factors associated with RM involvement to identify patients who would benefit from IFS analysis.
METHODS: We retrospectively analyzed patients who underwent gastrectomy with curative intent for gastric or esophagogastric junction (EGJ) cancer from 2000 to 2014 in six Italian hospitals. RM status was assessed by IFS analysis and/or definitive histopathology examination. A set of 21 potential risk factors were compared in a multivariate analysis between patients with positive RMs on IFS analysis or definitive histopathology examination and a control cohort of similar patients with negative RMs, with the samples stratified into three subgroups (T1, T2-T4 Lauren intestinal pattern, T2-T4 Lauren diffuse/mixed pattern).
RESULTS: One hundred forty-five patients had positive RMs. Survival was significantly worse in positive RM patients than in negative RM patients (89.5 months vs 28.9 months). Multivariate analysis showed that in T1 cancers a margin distance of less than 2 cm is a risk factor for RM involvement (odds ratio 15.7), in T2-T4 intestinal pattern cancers, serosa invasion (odds ratio 6.0), EGJ location (odds ratio 4.1), and a margin distance of less than 3 cm (odds ratio 4.0) are independent risk factors, and in T2-T4 diffuse/mixed pattern cancers, lymphatic infiltration (odds ratio 4.2), tumor diameter greater than 4 cm (odds ratio 3.5), EGJ location (odds ratio 2.8), and serosa invasion (odds ratio 2.2) are independent risk factors.
CONCLUSIONS: Survival after gastrectomy is negatively affected by positive RMs. IFS analysis should be routinely used in patients with a high risk of positive RMs, especially in diffuse pattern cancers.

Entities:  

Keywords:  Esophagogastric junction; Gastrectomy; Gastric cancer; Intraoperative frozen section; Resection margins; Risk factors

Mesh:

Year:  2016        PMID: 26732876     DOI: 10.1007/s10120-015-0589-6

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  28 in total

1.  Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection.

Authors:  Jung-Woo Woo; Keun Won Ryu; Ji Yeon Park; Bang Wool Eom; Mi Jung Kim; Hong Man Yoon; Sook Ryun Park; Myeong-Cherl Kook; Il Ju Choi; Young-Woo Kim; Young-Iee Park
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

2.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Clinical impact of tumor infiltration at the transected surgical margin during gastric cancer surgery.

Authors:  Ju-Hee Lee; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim; Hyuk-Joon Lee; Han-Kwang Yang
Journal:  J Surg Oncol       Date:  2012-04-09       Impact factor: 3.454

4.  Intraoperative frozen section margin evaluation in gastric cancer of the cardia surgery.

Authors:  Jian Guo Shen; Jae Ho Cheong; Woo Jin Hyung; Junuk Kim; Seung Ho Choi; Sung Hoon Noh
Journal:  Hepatogastroenterology       Date:  2006 Nov-Dec

5.  Accuracy, utility, and cost of frozen section margins in head and neck cancer surgery.

Authors:  L J DiNardo; J Lin; L S Karageorge; C N Powers
Journal:  Laryngoscope       Date:  2000-10       Impact factor: 3.325

6.  Local recurrence of gastric adenocarcinomas after gastrectomy.

Authors:  D N Papachristou; J G Fortner
Journal:  J Surg Oncol       Date:  1981       Impact factor: 3.454

7.  Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy.

Authors:  K Nakamura; T Ueyama; T Yao; Z X Xuan; K Ambe; Y Adachi; Y Yakeishi; A Matsukuma; M Enjoji
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

Review 8.  The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.

Authors:  Eric K Rowinsky
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

9.  Which Is the Optimal Extent of Resection in Middle Third Gastric Cancer between Total Gastrectomy and Subtotal Gastrectomy?

Authors:  Ji Hyun Lee; Yong Il Kim
Journal:  J Gastric Cancer       Date:  2010-12-31       Impact factor: 3.720

10.  Effect of microscopic resection line disease on gastric cancer survival.

Authors:  S H Kim; M S Karpeh; D S Klimstra; D Leung; M F Brennan
Journal:  J Gastrointest Surg       Date:  1999 Jan-Feb       Impact factor: 3.267

View more
  16 in total

Review 1.  Distant nodal metastasis: is it always an unresectable disease?

Authors:  Gian Luca Baiocchi; Andrea Celotti; Sarah Molfino; Paolo Baggi; Antonio Tarasconi; Gianluca Baronio; Luca Arru; Federico Gheza; Guido Tiberio; Nazario Portolani
Journal:  Transl Gastroenterol Hepatol       Date:  2017-01-05

Review 2.  [R1 resection for gastric carcinoma].

Authors:  K Ridwelski; J Fahlke; M Huß; R Otto; S Wolff
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

3.  Short-term outcomes after laparoscopic versus open transhiatal resection of Siewert type II adenocarcinoma of the esophagogastric junction.

Authors:  Shizuki Sugita; Takahiro Kinoshita; Akio Kaito; Masahiro Watanabe; Hideki Sunagawa
Journal:  Surg Endosc       Date:  2017-06-27       Impact factor: 4.584

Review 4.  Prevention and treatment of a positive proximal margin after gastrectomy for cardia cancer.

Authors:  Eider Talavera-Urquijo; Andrew R Davies; Bas P L Wijnhoven
Journal:  Updates Surg       Date:  2022-07-16

5.  The Feasibility and Safety of Preoperative Fluorescence Marking with Indocyanine Green (ICG) in Laparoscopic Gastrectomy for Gastric Cancer.

Authors:  Yuki Ushimaru; Takeshi Omori; Yoshiyuki Fujiwara; Yoshitomo Yanagimoto; Keijiro Sugimura; Kazuyoshi Yamamoto; Jeong-Ho Moon; Hiroshi Miyata; Masayuki Ohue; Masahiko Yano
Journal:  J Gastrointest Surg       Date:  2018-08-06       Impact factor: 3.452

Review 6.  Resection line involvement after gastric cancer treatment: handle with care.

Authors:  Paolo Morgagni; Giuliano La Barba; Eleonora Colciago; Giovanni Vittimberga; Giorgio Ercolani
Journal:  Updates Surg       Date:  2018-06-23

7.  Intraoperative gastroscopy to determine proximal resection margin during totally laparoscopic gastrectomy for patients with upper third gastric cancer.

Authors:  Peng Yuan; Yan Yan; Yongning Jia; Jing Wang; Ziyu Li; Qi Wu
Journal:  J Gastrointest Oncol       Date:  2021-02

8.  Long-term Outcomes of Laparoscopic Versus Open Transhiatal Approach for the Treatment of Esophagogastric Junction Cancer.

Authors:  Yoontaek Lee; Sa-Hong Min; Ki Bum Park; Young Suk Park; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim
Journal:  J Gastric Cancer       Date:  2019-01-31       Impact factor: 3.720

9.  Population-Based Study on Risk Factors for Tumor-Positive Resection Margins in Patients with Gastric Cancer.

Authors:  Leonie R van der Werf; Charlotte Cords; Ivo Arntz; Eric J T Belt; Ivan M Cherepanin; Peter-Paul L O Coene; Erwin van der Harst; Joos Heisterkamp; Barbara S Langenhoff; Bas Lamme; Mark I van Berge Henegouwen; Sjoerd M Lagarde; Bas P L Wijnhoven
Journal:  Ann Surg Oncol       Date:  2019-04-22       Impact factor: 5.344

10.  Optimal proximal resection margin distance for gastrectomy in advanced gastric cancer.

Authors:  Amy Kim; Beom Su Kim; Jeong Hwan Yook; Byung Sik Kim
Journal:  World J Gastroenterol       Date:  2020-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.